Michael Morneau insider trades: Viking Therapeutics (VKTX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Michael reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 31, 2018 | VKTX | ↓ Sell | 21,551 | $9.25 | $199K | Direct | May 31, 2018 (0d) |
| Jul 11, 2013 | TSRX | ↓ Sell | 20,000 | $9.75 | $195K | Direct | Jul 12, 2013 (1d) |
| May 14, 2013 | TSRX | ↓ Sell | 20,000 | $7.75 | $155K | Direct | May 16, 2013 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other VKTX insiders
Open-market trades in the last 12 months
About Michael Morneau's insider trades
Michael Morneau is VP, Finance and Administration at Viking Therapeutics (VKTX). Since May 14, 2013, Michael has reported no open-market purchases and 3 sales worth $549K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (14 filings), shares withheld for taxes (8 filings), option exercises (2 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every VKTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.